Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05693766 · ClinicalTrials.gov registry record · Phase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
A Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma, sponsored by Sonya Reid.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 3
- Study locations
NCT05693766 is a Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma that is actively recruiting participants, run by Sonya Reid. The registered enrollment target is 64 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05693766, a Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma, is actively recruiting participants, sponsored by Sonya Reid.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Conditions Studied
Interventions
- DRUG Capecitabine
- OTHER Endocrine-therapy
- OTHER MammoPrint ® and BluePrint assays
Study Locations (3)
Alabama
- University of Alabama Birmingham - Birmingham
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2037-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05693766
The ClinicalTrials.gov registry entry for NCT05693766 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Sonya Reid, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT05693766 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05693766 about?
NCT05693766 is a clinical study titled "Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort". This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
What is the current status of trial NCT05693766?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-28. Estimated completion is 2037-08-31.
What conditions does trial NCT05693766 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Invasive Mammary Carcinoma.
What interventions are being tested in trial NCT05693766?
The interventions under investigation include: Capecitabine (DRUG), Endocrine-therapy (OTHER), MammoPrint ® and BluePrint assays (OTHER).
Who is sponsoring clinical trial NCT05693766?
This trial is sponsored by Sonya Reid, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05693766 being conducted?
This trial has 3 study locations across Alabama, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.